

FORM PT01449
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2500.116US3

SERIAL NO.

09/250,056

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT

JAMES D. MARKS et al.

FILED

February 12, 1999

GROUP

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
LA	A1	5 1 6 9 7 7 4	12/92 12/72	Frankel et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS.? (YES/NO)
LA	B1	92 / 2 2 6 5 3	12/92	PCT			Yes


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

LA	C1	Altenschmidt et al., "Targeted Therapy of Schwannoma Cells in Immunocompetent Rats with an erbB2-Specific Antibody-Toxin", International Journal of Cancer, 26 September 1997, Vol. 73, No. 1, pp. 117-124.					
	C2	Barry, et al., "Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries", Nature Medicine, March 1996, Vol. 2, No. 3, pp. 299-305.					
	C3	Fominaya, et al., "Target Cell-specific DNA Transfer Mediated by a Chimeric Multidomain Protein", Journal of Biological Chemistry, May 3, 1996, Vol. 271, No. 18, pp. 10560-10568.					
	C4	Hart, et al., "Cell Binding and Internalization by Filamentous Phage Displaying a Cyclic Arg-Gly-Asp-containing Peptide", Journal of Biological Chemistry, April 29, 1994, Vol. 269, No. 17, pp. 12468-12474.					
	C5	Okayama, et al., "Bacteriophage Lambda Vector for Transducing a cDNA Clone Library into Mammalian Cells", Molecular and Cellular Biology, May 1985, Vol. 5, No. 5, pp. 1136-1142.					
	C6	Larocca et al., "Targeting Bacteriophage to Mammalian Cell Surface Receptor for Gene Delivery", Human Gene Therapy, November 1, 1998, Vol. 9, pp. 2393-2399.					
	C7	Kirpotin et al., "Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells in Vitro", Biochemistry, January 7, 1997, Vol 36, No. 1, pp. 66-75.					
✓	C8	Schier, et al., "In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library", Immunotechnology, 1995, Vol. 1, pp. 73-81.					

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PT01449 (REV. 8-83)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2500.116US3	SERIAL NO. 09/250,056
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>				APPLICANT JAMES D. MARKS et al.	
				FILED February 12, 1999	GROUP
U. S. PATENT DOCUMENTS					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent pages, Etc.)</i>					
LW	C9	Schier, et al., "Identification of functional and structural amino-acid residues by parsimonious mutagenesis", Gene, March 9, 1996, Vol. 169, No. 2, pp. 147-155.			
/	C10	Schier, et al., "Efficient <i>in vitro</i> affinity maturation of phage antibodies using BIAcore guided selections", Hum. Antibod. Hybridomas, 1996, Vol 3, No. 7, pp. 97-105.			
/	C11	Schier, et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using Affinity-driven Selection", Journal of Molecular Biology, January 12, 1996, Vol. 255, No. 1, pp. 28-43.			
/	C12	Schier, et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site", Journal of Molecular Biology, January 12, 1996, Vol. 263, No. 4, pp. 551-567.			
/	C13	Slamon, et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer, American Association for the Advancement of Science, 12 May 1989, Vol. 244, No. 4905, pp. 707-712.			
/	C14	Yokoyama-Kobayashi, et al., "Recombinant fl Phage Particles Can Transfect Monkey COS-7 Cells by DEAE Dextran Method", Biochemical and Biophysical Research Communication, April 30, 1993, Vol. 192, No. 2, pp 935-939.			
/	C15	Borrebaeck Carl A.K., "Strategy for the production of human monoclonal antibodies using in vitro activated B cells", Journal of Immunological Methods, Vol. 123, 1989, pp. 157-165.			
/	C16	Disis, et al., "Existent T-Cell and Antibody Immunity to HER-2/neu Protein in Patients with Breast Cancer", Cancer Research, Vol. 54, January 1, 1994, pp. 16-20.			
/	C17	Huston, et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ", Proceedings of the National Academy of Sciences, Vol. 85, August 1988, pp. 5879-5883.			
/	C18	Vallera Daniel A., "Immunotoxins: Will Their Clinical Promise be Fulfilled", Blood: The Journal of The Americal Society of Hematology, Vol. 83, No. 2, January 15, 1994, pp. 309-317.			
/	C19	Soderlind, et al., "Phage Display Technology in Antibody Engineering: Design of Phagemid Vectors and <i>in vitro</i> Maturation Systems", Immunological Reviews, 1992, No. 130, pp. 109-124.			
/	C20	Trail, et al., "Cure of Xenografted Human Carcinomas by BR96-Doxorubicin Immunoconjugates", Science, July 9, 1993, Vol. 261, pp. 212-215.			
EXAMINER 				DATE CONSIDERED 10/21/99	
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to					

FORM PT01449
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2500.116US3

SERIAL NO.

09/250,056

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT

JAMES D. MARKS et al.

FILED

February 12, 1999

GROUP

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

144	C21	Weiner, et al., Phase I Evaluation of an Anti-Breast Carcinoma Monoclonal Antibody 260F9-Recombinant Ricin a Chain Immunoconjugate", Cancer Research, Vol. 49, July 15, 1989, pp. 4062-4067.
	C22	Riethmuller, et al., "Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers", Current Opinion in Immunology, 1992, Vol. 4, pp. 647-655.
	C23	Brinkmann, et al., "A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of <i>Pseudomonas</i> exotoxin", Proceedings of the National Academy of Sciences, January 1993, Vol. 90, pp. 547-551.
	C24	Colcher, et al., "Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies", Cancer Research, August 15, 1988, Vol. 48, pp. 4597-4603.
	C25	Gallinger, et al., "Comparative Dual Label Study of First and Second Generation Antitumor-associated Glycoprotein-72 Monoclonal Antibodies in Colorectal Cancer Patients", Cancer Research, January 15, 1993, Vol. 53, pp. 273-278.
	C26	Adams, et al., "Highly Specific <i>in Vivo</i> Tumor Targeting by Monovalent and Divalent Forms of 741F8 Anti-c-erbB-2 Single Chain Fv.
	C27	Hoogenboom, et al., "Building Antibodies from their Genes", Immunological Reviews, 1992, No. 130, pp. 41-68.
	C28	Marks, et al., "By-passing Immunization Human: Human antibodies from V-gene Libraries Displayed on Phage", Journal of Mol. Biology, 1991, Vol. 222, pp. 581-597.
	C29	Marks, et al., "By-passing Immunization Human: Building High Affinity Human Antibodies by Chain Shuffling", Bio/Technology, July 1992, Vol. 10., pp. 779-783.
	C30	Hawkins, et al., "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation", Journal of Mol. Biology, 1992, Vol. 226, pp. 889-896.
	C31	Reichmann, et al., "Phage Display and Selection of a Site-Directed Randomized Single-Chain Antibody Fv Fragment for Its Affinity Improvement", Biochemistry, 1993, Vol. 32, pp. 8848-8855.
	C32	McCafferty, et al., "Phage antibodies: filamentous phage displaying antibody variable domains", Nature, December 6, 1990, Vol. 348, pp. 552-554.
V	C33	Griffiths, et al., "Human anti-self antibodies with high specificity from phage display libraries", EMBO Journal, 1993, Vol. 12, No. 2, pp. 725-734.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to

ATTACH TO #10


FORM PT01449
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2500.116US3

SERIAL NO.

09/250,056



INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT

James D. Marks et al.

FILED

February 12, 1999

GROUP

1642

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUB CLASS	FILING DATE
LQD	B1	5	8	8	5	7	9	3		3/23/99	Griffeths et al.	-	-	
LQD	B2	5	7	3	3	7	8	2		3/31/98	Dorai et al.	-	-	
LQD	B3	5	6	9	6	2	3	7		12/9/97	Fitzgerald et al.	-	-	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUB CLASS	TRANS.? (YES/NO)
LQA	B4	9	4	2	6	7	8	7		11/24/94	PCT	-	-	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

LQA	B5	Larocca et al. (1999) "Gene Transfer to Mammalian Cells Using Genetically Targeted Filamentous Bacteriophage," <i>FASEB Journal</i> , 13(6):727-734												
LQA	B6	PCT/US99/07395, International Search Report, August 1999												
LQA	B7	PCT/US99/07398, International Search Report, August 1999												
LQA	B8	PCT/US99/08468, International Search Report, August 1999												

EXAMINER

DATE CONSIDERED

10/28/99

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.